Genmab AS (GMAB)
NASDAQ · Healthcare · Biotechnology
Genmab AS is a Healthcare company with a market capitalization of $19.78B and a trailing P/E ratio of 25.0.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025 · in DKK
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 7, 2026 | $0.13 | $0.19 | -31.6% |
| Q4 2025 | February 17, 2026 | $0.21 | $0.37 | -43.2% |
| Q3 2025 | November 6, 2025 | $0.65 | $0.45 | +44.4% |
| Q2 2025 | August 7, 2025 | $0.54 | $0.39 | +38.5% |
| Q1 2025 | May 8, 2025 | $0.31 | $0.23 | +34.8% |
| Q4 2024 | February 12, 2025 | $0.84 | $0.28 | +200.0% |
Short Interest
FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.
| Settlement | Shares Short | % of Shares Out | Days to Cover | Change |
|---|---|---|---|---|
| July 15, 2026 | 7,558,770 | — | 3.2 | -9.3% |
| June 30, 2026 | 8,329,932 | — | 4.7 | -3.0% |
| June 15, 2026 | 8,588,992 | — | 5.8 | -14.5% |
| May 29, 2026 | 10,048,894 | — | 4.6 | -1.1% |
| May 15, 2026 | 10,160,510 | — | 4.9 | +19.6% |
| April 30, 2026 | 8,496,589 | — | 5.2 | +7.2% |
| April 15, 2026 | 7,925,760 | — | 5.4 | -7.6% |
| March 31, 2026 | 8,576,449 | — | 5.5 | -3.6% |
Other Biotechnology Stocks
Frequently Asked Questions
What is Genmab AS's market cap?
As of August 13, 2026, Genmab AS (GMAB) has a market capitalization of $19.78B.
What is Genmab AS's P/E ratio?
Genmab AS trades at a trailing price-to-earnings (P/E) ratio of 25.0. Its forward P/E is 18.4.
Does Genmab AS pay a dividend?
Genmab AS does not currently pay a dividend.
What sector is GMAB in?
Genmab AS is in the Healthcare sector, specifically the Biotechnology industry.
What is Genmab AS's short interest?
As of the July 15, 2026 FINRA settlement, 7,558,770 GMAB shares were sold short. Days to cover: 3.2. FINRA publishes short interest twice a month, about nine business days after each settlement date.
What was Genmab AS's revenue?
In its latest reported fiscal year (ending December 31, 2025), Genmab AS reported revenue of 3.72B DKK and net income of 963.76M DKK.
Ask your own questions about GMAB
Try mrmarket.ai freeData as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.